ABSTRACT
El cáncer colorrectal es una patología común que causa aproximadamente 861,000 muertes al año. Se presenta el caso de un paciente masculino de 50 años, con hipertensión arterial y Diabetes mellitus tipo II, con diagnóstico de neoplasia en colon descendente, al cual se le realizó procedimiento mínimamente invasivo, posterior a marcación tumoral con azul de metileno por medio de endoscopia de vías digestiva bajas. Postoperatorio adecuado, sin complicaciones. El tratamiento de elección para el cáncer colorrectal sin metástasis es la exeresis oncológica. Actualmente, el manejo quirúrgico recomendado es por medio de procedimiento mínimamente invasivo, sin embargo, es un desafío puesto que en algunos casos la identificación de la lesión es difícil y adicionalmente requiere una curva de aprendizaje pronunciada. Por lo anterior, utilizamos el azul de metileno para la marcación del tumor previo procedimiento, con excelentes resultados, sin complicaciones. La marcación tumoral con azul de metileno previa al procedimiento mínimamente invasivo es seguro, útil, económico y de bajo riesgo.
Colorectal cancer is a common pathology, causing approximately 861,000 deaths a year. The case a 50-year-old male patient, with arterial hypertension and type II diabetes mellitus, with a diagnosis of neoplasia in the descending colon, which was performed minimally invasive procedure, after tumor marking with methylene blue by means of endoscopy of lower digestive tracts. Adequate postoperative period, without complications. The treatment of choice for colorectal cancer without metastasis is oncological exeresis. Currently the recommended surgical management is by means of a minimally invasive procedure, however, it is a challenge since in some cases the identification of the lesion is difficult and additionally requires a pronounced learning curve. Therefore, we use methylene blue for the marking of the tumor after the procedure, with excellent results, without complications. Methylene blue tumor marking prior to the minimally invasive procedure is safe, useful, inexpensive, and low risk.
ABSTRACT
Pseudomonas aeruginosa is one of the Multi-Drug-Resistant organisms most frequently isolated worldwide and, because of a shortage of new antibiotics, bacteriophages are considered an alternative for its treatment. Previously, P. aeruginosa phages were isolated and best candidates were chosen based on their ability to form clear plaques and their host range. This work aimed to characterize one of those phages, ΦPan70, preliminarily identified as a good candidate for phage-therapy. We performed infection curves, biofilm removal assays, transmission-electron-microscopy, pulsed-field-gel-electrophoresis, and studied the in vivo ΦPan70 biological activity in the burned mouse model. ΦPan70 was classified as a member of the Myoviridae family and, in both planktonic cells and biofilms, was responsible for a significant reduction in the bacterial population. The burned mouse model showed an animal survival between 80% and 100%, significantly different from the control animals (0%). However, analysis of the ΦPan70 genome revealed that it was 64% identical to F10, a temperate P. aeruginosa phage. Gene annotation indicated ΦPan70 as a new, but possible temperate phage, therefore not ideal for phage-therapy. Based on this, we recommend genome sequence analysis as an early step to select candidate phages for potential application in phage-therapy, before entering into a more intensive characterization.
